These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32974491)

  • 1. Assessment of urinary pharmacokinetic and pharmacodynamic profiles of faropenem against extended-spectrum
    Harada K; Shimizu T; Miyashita N; Hikasa Y
    Access Microbiol; 2019; 1(1):e000004. PubMed ID: 32974491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum β-Lactamase-Producing
    Harada K; Shimizu T; Kawaguchi K; Furuhashi T; Ishihara G
    Antibiotics (Basel); 2020 May; 9(5):. PubMed ID: 32380640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling.
    Shimizu T; Harada K; Manabe S; Tsukamoto T; Ito N; Hikasa Y
    J Med Microbiol; 2017 May; 66(5):616-621. PubMed ID: 28470147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli.
    Gandra S; Choi J; McElvania E; Green SJ; Harazin M; Thomson RB; Dantas G; Singh KS; Das S
    Int J Antimicrob Agents; 2020 Mar; 55(3):105902. PubMed ID: 31954833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of faropenem for patients with acute cystitis caused by extended spectrum β-lactamase producing Escherichia coli.
    Fujino K; Hiyama Y; Uehara T; Ichihara K; Hashimoto J; Fujii S; Shinagawa M; Takahashi S; Masumori N
    J Infect Chemother; 2017 May; 23(5):336-338. PubMed ID: 27916471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is frequently detected as a pathogen of urinary tract infection in nursing home residents].
    Yamamoto A
    Nihon Ronen Igakkai Zasshi; 2011; 48(5):530-8. PubMed ID: 22323032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae.
    Mushtaq S; Hope R; Warner M; Livermore DM
    J Antimicrob Chemother; 2007 May; 59(5):1025-30. PubMed ID: 17353220
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Abdelraouf K; Stainton SM; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
    Yamamoto A; Yamasaki K
    Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Cho SY; Choi SM; Park SH; Lee DG; Choi JH; Yoo JH
    Korean J Intern Med; 2016 Jan; 31(1):156-61. PubMed ID: 26767869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
    Gill SC; Rubino CM; Bassett J; Miller L; Ambrose PG; Bhavnani SM; Beaudry A; Li J; Stone KC; Critchley I; Janjic N; Heine HS
    Antimicrob Agents Chemother; 2010 May; 54(5):1678-83. PubMed ID: 20145081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral amoxicillin-clavulanic Acid treatment in urinary tract infections caused by extended-spectrum Beta-lactamase-producing organisms.
    Beytur A; Yakupogullari Y; Oguz F; Otlu B; Kaysadu H
    Jundishapur J Microbiol; 2015 Jan; 8(1):e13792. PubMed ID: 25763134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
    BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?
    Ahn ST; Kim SW; Kim JW; Park HS; Moon DG; Oh MM
    J Infect Chemother; 2019 Jul; 25(7):498-502. PubMed ID: 30852104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.